1. Home
  2. DERM vs TNXP Comparison

DERM vs TNXP Comparison

Compare DERM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

N/A

Current Price

$6.24

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$9.56

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DERM
TNXP
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
199.7M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
DERM
TNXP
Price
$6.24
$9.56
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$12.67
N/A
AVG Volume (30 Days)
157.2K
484.8K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
91.75
EPS
N/A
N/A
Revenue
$61,858,000.00
$13,107,000.00
Revenue This Year
$39.72
$558.11
Revenue Next Year
$63.24
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
10.20
29.85
52 Week Low
$4.31
$9.81
52 Week High
$9.56
$69.65

Technical Indicators

Market Signals
Indicator
DERM
TNXP
Relative Strength Index (RSI) 41.81 37.21
Support Level $5.80 N/A
Resistance Level $6.59 $13.18
Average True Range (ATR) 0.37 0.88
MACD -0.13 -0.21
Stochastic Oscillator 17.93 3.49

Price Performance

Historical Comparison
DERM
TNXP

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: